We
prepared the condensed consolidated financial statements following the
requirements of the Securities and Exchange Commission (SEC) for interim
reporting. As permitted under those rules, certain footnotes or other financial
information that are normally required by accounting principles generally
accepted in the United States of America (U.S. GAAP) can be condensed or
omitted. Balance sheet amounts and operating results for subsidiaries operating
outside the U.S. are as of and for the three-month and six-month periods ended
May 24, 2009, and May 25, 2008. Subsequent events have been evaluated through
August 6, 2009.
We made
certain reclassifications to prior-period amounts to conform to the
second-quarter and six-month 2009 presentations related to the presentation of
noncontrolling interests as a result of adopting a new accounting standard (see
Note 2. Adoption of New
Accounting Policies).
Revenues,
expenses, assets and liabilities can vary during each quarter of the year.
Therefore, the results and trends in these interim financial statements may not
be representative of those for the full year.
We are
responsible for the unaudited financial statements included in this
document. The financial statements include all normal and recurring
adjustments that are considered necessary for the fair presentation of our
financial position and operating results.
The
information included in this Quarterly Report on Form 10-Q should be read in
conjunction with the consolidated financial statements and accompanying notes
included in Pfizer s Annual Report on Form 10-K for the year ended December
31, 2008.
On
January 26, 2009, we announced that we entered into a definitive merger
agreement under which we will acquire Wyeth in a cash-and-stock transaction
valued on that date at $50.19 per share, or a total of $68 billion. While we
have taken actions and incurred costs associated with the pending transaction
that are reflected in our financial statements, the pending acquisition of Wyeth
will not be reflected in our financial statements until consummation. (See Note 14. Pending Acquisition of
Wyeth.)
Included in Other
current liabilities at June 28, 2009 are $1.5 billion of deferred income
taxes.
Note 2. Adoption of New
Accounting Policies
As of
March 30, 2009, we adopted Financial Accounting Standards Board (FASB) Staff
Position (FSP) No. Statement of Financial Accounting Standards (SFAS) 115-2 and
SFAS 124-2, Recognition and
Presentation of Other-Than-Temporary Impairments. FSP SFAS 115-2 and SFAS
124-2 amend the guidance for evaluating and measuring other-than-temporary
impairments for available-for-sale or held-to-maturity debt securities. The
adoption of FSP SFAS 115-2 and SFAS 124-2 did not have a significant impact on
our consolidated financial statements.
As of
March 30, 2009, we adopted FSP No. SFAS 157-4, Determining Fair Value When the
Volume and Level of Activity for the Asset or Liability Have Significantly
Decreased and Identifying Transactions That Are Not Orderly. FSP SFAS
157-4 provides additional guidance for estimating fair value in inactive markets
and the identification of disorderly transactions. FSP SFAS 157-4 was adopted
prospectively and did not have a significant impact on our consolidated
financial statements, but could impact the accounting for acquisitions after
adoption, including our pending acquisition of Wyeth, and other events, balances
and transactions measured at fair value.
As of
January 1, 2009, we adopted SFAS No. 141R, Business Combinations, as
amended. SFAS 141R, as amended, retains the purchase method of accounting for
acquisitions, but requires a number of changes, including changes in the way
assets and liabilities are recognized in purchase accounting. It also changes
the recognition of assets acquired and liabilities assumed arising from
contingencies, requires the capitalization of in-process research and
development costs at fair value and requires the expensing of
acquisition-related costs as incurred. The adoption of SFAS 141R, as amended,
did not impact our consolidated financial statements upon adoption, but will
impact the accounting for acquisitions after adoption, including our pending
acquisition of Wyeth.
PFIZER
INC. AND SUBSIDIARY COMPANIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
As of
January 1, 2009, we adopted FSP No. SFAS 142-3, Determination of the Useful Life of
Intangible Assets. FSP SFAS 142-3 amends the factors considered in
developing renewal or extension assumptions used to determine the useful life of
a recognized intangible asset. Among other things, in the absence of historical
experience, an entity will be required to consider assumptions used by market
participants. The adoption of FSP SFAS 142-3 did not impact our consolidated
financial statements upon adoption, but could impact the accounting for
acquisitions after adoption, including our pending acquisition of
Wyeth.
As of
January 1, 2009, we adopted the provisions of SFAS No. 157, Fair Value Measurements, as
amended, that we did not adopt as of January 1, 2008. SFAS 157, as amended,
defines fair value, expands related disclosure requirements and specifies a
hierarchy of valuation techniques based on the nature of the inputs used to
develop the fair value measures. The adoption of the remaining provisions of
SFAS 157, as amended, did not have a significant impact on our consolidated
financial statements upon adoption, but will impact the accounting for
acquisitions after adoption, including our pending acquisition of Wyeth, and
other events, balances and transactions measured at fair value.
As of
January 1, 2009, we adopted SFAS No. 160, Noncontrolling Interests in
Consolidated Financial Statements, an amendment of Accounting Research
Bulletin No. 51, Consolidated Financial
Statements. SFAS 160 provides guidance for the accounting, reporting and
disclosure of noncontrolling interests, previously referred to as minority
interests. A noncontrolling interest represents the portion of equity (net
assets) in a subsidiary not attributable, directly or indirectly, to a parent.
The adoption of SFAS 160 resulted in a number of changes to the presentation of
our consolidated financial statements, but the amounts associated with
noncontrolling interests are not significant. SFAS 160 could impact our
accounting for acquisitions after adoption, where we do not acquire 100% of the
entity, and our accounting for the deconsolidations of
subsidiaries.
As of
January 1, 2009, we adopted Emerging Issues Task Force (EITF) Issue No. 07-1,
Accounting for Collaborative
Arrangements. EITF 07-1 provides guidance on determining whether an
arrangement constitutes a collaborative arrangement within the scope of the
Issue; how costs incurred and revenue generated on sales to third parties should
be reported in the income statement; how an entity should characterize payments
on the income statement; and what
participants should disclose in the notes to the financial statements about a
collaborative arrangement. The adoption of EITF 07-1 did not have a significant
impact on our consolidated financial statements, and additional disclosures have
been provided. (See Note 4.
Collaborative Arrangements.)
As of
January 1, 2009, we adopted EITF Issue No. 08-3, Accounting by Lessees for
Maintenance Deposits. EITF 08-3 provides guidance that maintenance
deposits paid by a lessee and subsequently refunded only if a lessee fulfills a
maintenance obligation will be accounted for as a deposit asset. The adoption of
EITF 08-3 did not have a significant impact on our consolidated financial
statements.
As of
January 1, 2009, we adopted EITF Issue No. 08-6, Equity Method Investment Accounting
Considerations. EITF 08-6 clarifies how to account for certain
transactions involving equity method investments in areas such as: how to
determine the initial carrying value of the investment; how to allocate the
difference between the investor s carrying value and the investor s share of the
underlying equity of the investment; how to perform an impairment assessment of
underlying intangibles held by the investee; how to account for the investee s
issuance of additional shares; and how to account for an investment on the cost
method when it had been previously accounted for under the equity method. The
adoption of EITF 08-6 did not have a significant impact on our consolidated
financial statements, but could impact the accounting for equity method
investments after adoption.
As of
January 1, 2009, we adopted EITF Issue No. 08-7, Accounting for Defensive Intangible
Assets. EITF 08-7 clarifies the accounting for certain separately
identifiable assets, which an acquirer does not intend to actively use but
intends to hold to prevent its competitors from obtaining access to them. EITF
08-7 requires an acquirer to account for a defensive intangible asset as a
separate unit of accounting, which should be amortized to expense over the
period the asset diminishes in value. The adoption of EITF 08-7 did not have a
significant impact on our consolidated financial statements, but could impact
the accounting for acquisitions after adoption.
Note 3.
Acquisitions
In the
second quarter of 2008, we acquired Encysive Pharmaceuticals Inc. (Encysive), a
biopharmaceutical company whose main asset is Thelin, which is used for the
treatment of pulmonary arterial hypertension. The cost of acquiring Encysive,
through a tender offer and subsequent merger, was approximately
$200 million, including transaction costs. Upon our acquisition of
Encysive, Encysive's change of control repurchase obligations under its
outstanding $130 million 2.5% convertible notes were triggered and, as a result,
Encysive repurchased the convertible notes in consideration for their par value
plus accrued interest in June 2008. In addition, in the second quarter of 2008,
we acquired Serenex, Inc. (Serenex), a privately held biotechnology company,
whose main asset is SNX-5422, an oral Heat Shock Protein 90 (Hsp90) for the
potential treatment of solid tumors and hematological malignancies and an
extensive Hsp90 inhibitor compound library, which has potential uses in treating
cancer, inflammatory and neurodegenerative diseases. In connection with these
acquisitions, through the second quarter of 2008, we recorded $156 million in
Acquisition-related in-process
research and development charges and approximately $450 million in
intangible assets.
PFIZER
INC. AND SUBSIDIARY COMPANIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
In the
first quarter of 2008, we acquired CovX, a privately held biotherapeutics
company specializing in preclinical oncology and metabolic research and the
developer of a biotherapeutics technology platform. Also in the first quarter of
2008, we acquired all the outstanding shares of Coley Pharmaceutical Group,
Inc., (Coley), a biopharmaceutical company specializing in vaccines and drug
candidates designed to fight certain cancers, allergy and asthma disorders, and
autoimmune diseases, for approximately $230 million. In connection with these
and two smaller acquisitions related to Animal Health, we recorded approximately
$398 million in Acquisition-related in-process
research and development charges during the first quarter of 2008. In the second quarter of
2009, we resolved a contingency associated with CovX and recognized $20 million
in Acquisition-related
in-process research and development charges.
Note 4. Collaborative
Arrangements
In the
normal course of business, we enter into collaborative arrangements with respect
to in-line medicines, as well as medicines in development that require
completion of research and regulatory approval. Collaborative arrangements are
contractual agreements with third parties that involve a joint operating
activity, typically a research and/or commercialization effort, where both we
and our partner are active participants in the activity and are exposed to the
significant risks and rewards of the activity. Our rights and obligations under
our collaborative arrangements vary. For example, we have agreements to
co-promote pharmaceutical products discovered by other companies, and we have
agreements where we partner to co-develop and/or participate together in
commercializing, marketing, promoting, manufacturing, and/or distributing a drug
product.
Payments
to or from our collaboration partners are presented in the statement of income
based on the nature of the arrangement (including its contractual terms), the
nature of the payments and applicable accounting guidance. Under co-promotion
agreements, we record the amounts received from our partners as alliance
revenues, a component of Revenues, when our
co-promotion partners are the principal in the transaction and we receive a
share in their net sales or profits. Alliance revenues are recorded when our
co-promotion partners ship the product and title passes to their customer.
Expenses for selling and marketing these products are included in Selling, informational and